What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid a year of exceptional stock appreciation.
Overview
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics (NASDAQ:RAPP), reported the sale of 10,000 shares of common stock for approximately ~$416,000 across multiple open-market transactions on June 30, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average reported price ($41.58). Post-transaction value based on July 1 closing price.
Details
* 1-year price change calculated using July 1st, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.